JP2023126540A5 - - Google Patents

Info

Publication number

JP2023126540A5

JP2023126540A5 JP2023116961A JP2023116961A JP2023126540A5 JP 2023126540 A5 JP2023126540 A5 JP 2023126540A5 JP 2023116961 A JP2023116961 A JP 2023116961A JP 2023116961 A JP2023116961 A JP 2023116961A JP 2023126540 A5 JP2023126540 A5 JP 2023126540A5

Authority

JP

Japan

Prior art keywords

endoxifen

enteric coated

oral formulation

coated oral

less

Prior art date

2023-07-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 claims description 819
• 239000000203 mixture Substances 0.000 claims description 748
• 238000000034 method Methods 0.000 claims description 245
• 150000001875 compounds Chemical class 0.000 claims description 233
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 190
• 238000009472 formulation Methods 0.000 claims description 190
• 150000003839 salts Chemical class 0.000 claims description 159
• 230000001419 dependent effect Effects 0.000 claims description 137
• 229940088597 hormone Drugs 0.000 claims description 133
• 239000005556 hormone Substances 0.000 claims description 133
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 111
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 99
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 94
• 208000030270 breast disease Diseases 0.000 claims description 91
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 86
• 229960001603 tamoxifen Drugs 0.000 claims description 86
• 206010006187 Breast cancer Diseases 0.000 claims description 84
• 208000026310 Breast neoplasm Diseases 0.000 claims description 84
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 76
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
• 239000012458 free base Substances 0.000 claims description 59
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 59
• 238000011282 treatment Methods 0.000 claims description 54
• 208000017443 reproductive system disease Diseases 0.000 claims description 49
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 47
• 210000000481 breast Anatomy 0.000 claims description 41
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 39
• 206010006256 Breast hyperplasia Diseases 0.000 claims description 38
• 201000000079 gynecomastia Diseases 0.000 claims description 34
• 239000012535 impurity Substances 0.000 claims description 29
• 206010020718 hyperplasia Diseases 0.000 claims description 23
• 239000006186 oral dosage form Substances 0.000 claims description 23
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 21
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 20
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 claims description 20
• 201000007273 ductal carcinoma in situ Diseases 0.000 claims description 20
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
• 208000028176 atypical lobular breast hyperplasia Diseases 0.000 claims description 19
• 201000005389 breast carcinoma in situ Diseases 0.000 claims description 19
• 201000011059 lobular neoplasia Diseases 0.000 claims description 19
• 230000000694 effects Effects 0.000 claims description 18
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 16
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 16
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 16
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 16
• 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 16
• 201000010881 cervical cancer Diseases 0.000 claims description 16
• 208000006155 precocious puberty Diseases 0.000 claims description 16
• 208000013139 vaginal neoplasm Diseases 0.000 claims description 16
• 208000028060 Albright disease Diseases 0.000 claims description 15
• 206010014733 Endometrial cancer Diseases 0.000 claims description 15
• 201000001853 McCune-Albright syndrome Diseases 0.000 claims description 15
• 206010033128 Ovarian cancer Diseases 0.000 claims description 15
• 206010047741 Vulval cancer Diseases 0.000 claims description 15
• 208000001061 polyostotic fibrous dysplasia Diseases 0.000 claims description 15
• 206010046766 uterine cancer Diseases 0.000 claims description 15
• 206010046885 vaginal cancer Diseases 0.000 claims description 15
• 201000005102 vulva cancer Diseases 0.000 claims description 15
• 229910001385 heavy metal Inorganic materials 0.000 claims description 13
• 238000004128 high performance liquid chromatography Methods 0.000 claims description 11
• 230000001580 bacterial effect Effects 0.000 claims description 10
• 235000002639 sodium chloride Nutrition 0.000 description 161
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 90
• 239000002775 capsule Substances 0.000 description 78
• 239000002904 solvent Substances 0.000 description 78
• MHJBZVSGOZTKRH-OCOZRVBESA-N 4-[(e)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)\C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-OCOZRVBESA-N 0.000 description 69
• 210000002381 plasma Anatomy 0.000 description 68
• 230000008569 process Effects 0.000 description 58
• 229940050410 gluconate Drugs 0.000 description 57
• 230000036470 plasma concentration Effects 0.000 description 57
• -1 for example Chemical class 0.000 description 53
• 239000003814 drug Substances 0.000 description 50
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
• 239000007787 solid Substances 0.000 description 39
• 239000007894 caplet Substances 0.000 description 38
• 239000003960 organic solvent Substances 0.000 description 36
• 235000019439 ethyl acetate Nutrition 0.000 description 33
• 239000003795 chemical substances by application Substances 0.000 description 31
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
• 208000035475 disorder Diseases 0.000 description 29
• 206010028980 Neoplasm Diseases 0.000 description 28
• 239000012452 mother liquor Substances 0.000 description 27
• 239000000546 pharmaceutical excipient Substances 0.000 description 27
• 201000011510 cancer Diseases 0.000 description 26
• 230000003111 delayed effect Effects 0.000 description 26
• 239000000523 sample Substances 0.000 description 26
• 229940079593 drug Drugs 0.000 description 25
• 239000012649 demethylating agent Substances 0.000 description 24
• 239000011541 reaction mixture Substances 0.000 description 24
• 238000010963 scalable process Methods 0.000 description 24
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
• 238000012360 testing method Methods 0.000 description 21
• 239000003638 chemical reducing agent Substances 0.000 description 20
• RGHNJXZEOKUKBD-KLVWXMOXSA-N L-gluconic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-KLVWXMOXSA-N 0.000 description 19
• 239000002253 acid Substances 0.000 description 19
• 239000008194 pharmaceutical composition Substances 0.000 description 19
• 239000003826 tablet Substances 0.000 description 19
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
• 239000002662 enteric coated tablet Substances 0.000 description 18
• 235000019441 ethanol Nutrition 0.000 description 18
• 150000003608 titanium Chemical class 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 17
• 238000002360 preparation method Methods 0.000 description 17
• 239000011701 zinc Substances 0.000 description 17
• 206010060862 Prostate cancer Diseases 0.000 description 16
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 16
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
• 208000037819 metastatic cancer Diseases 0.000 description 16
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 16
• 230000001850 reproductive effect Effects 0.000 description 16
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
• QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 15
• 230000003472 neutralizing effect Effects 0.000 description 15
• 229940124597 therapeutic agent Drugs 0.000 description 14
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
• 239000000370 acceptor Substances 0.000 description 13
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 13
• 229920000642 polymer Polymers 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
• 238000006519 Mcmurry reaction Methods 0.000 description 12
• 239000007884 disintegrant Substances 0.000 description 12
• 238000004821 distillation Methods 0.000 description 12
• 229960004756 ethanol Drugs 0.000 description 12
• 210000000936 intestine Anatomy 0.000 description 12
• KRIOVPPHQSLHCZ-UHFFFAOYSA-N propiophenone Chemical compound CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 12
• 238000010992 reflux Methods 0.000 description 12
• 210000001519 tissue Anatomy 0.000 description 12
• 201000009030 Carcinoma Diseases 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
• 239000007950 delayed release tablet Substances 0.000 description 11
• 239000003112 inhibitor Substances 0.000 description 11
• 201000010099 disease Diseases 0.000 description 10
• 239000002552 dosage form Substances 0.000 description 10
• 238000001953 recrystallisation Methods 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• RPFIMPDXTABYCN-BJFQDICYSA-N 4-[(z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 RPFIMPDXTABYCN-BJFQDICYSA-N 0.000 description 9
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• 229920002472 Starch Polymers 0.000 description 9
• 239000002246 antineoplastic agent Substances 0.000 description 9
• 210000004369 blood Anatomy 0.000 description 9
• 239000008280 blood Substances 0.000 description 9
• 210000004027 cell Anatomy 0.000 description 9
• 238000010520 demethylation reaction Methods 0.000 description 9
• 238000001640 fractional crystallisation Methods 0.000 description 9
• 239000000314 lubricant Substances 0.000 description 9
• 239000000463 material Substances 0.000 description 9
• 239000000843 powder Substances 0.000 description 9
• 230000002265 prevention Effects 0.000 description 9
• 238000001959 radiotherapy Methods 0.000 description 9
• 235000019698 starch Nutrition 0.000 description 9
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 8
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 8
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 8
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 8
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 8
• 239000011230 binding agent Substances 0.000 description 8
• 239000000090 biomarker Substances 0.000 description 8
• 238000002648 combination therapy Methods 0.000 description 8
• 238000013270 controlled release Methods 0.000 description 8
• 239000000945 filler Substances 0.000 description 8
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 8
• 239000008184 oral solid dosage form Substances 0.000 description 8
• 239000004014 plasticizer Substances 0.000 description 8
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 8
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 210000002784 stomach Anatomy 0.000 description 8
• 238000001356 surgical procedure Methods 0.000 description 8
• AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 7
• JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 7
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 7
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
• 229940041181 antineoplastic drug Drugs 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 102000015694 estrogen receptors Human genes 0.000 description 7
• 108010038795 estrogen receptors Proteins 0.000 description 7
• 238000000605 extraction Methods 0.000 description 7
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 239000000376 reactant Substances 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 239000008107 starch Substances 0.000 description 7
• 229940032147 starch Drugs 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• 230000003442 weekly effect Effects 0.000 description 7
• 229910052725 zinc Inorganic materials 0.000 description 7
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 6
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 6
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 6
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 6
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 6
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 6
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• 238000009098 adjuvant therapy Methods 0.000 description 6
• 235000010443 alginic acid Nutrition 0.000 description 6
• 229920000615 alginic acid Polymers 0.000 description 6
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• 210000001072 colon Anatomy 0.000 description 6
• 230000001335 demethylating effect Effects 0.000 description 6
• 230000008030 elimination Effects 0.000 description 6
• 238000003379 elimination reaction Methods 0.000 description 6
• 239000002702 enteric coating Substances 0.000 description 6
• 238000009505 enteric coating Methods 0.000 description 6
• UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 description 6
• 229960002949 fluorouracil Drugs 0.000 description 6
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 6
• FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 6
• 229910052749 magnesium Inorganic materials 0.000 description 6
• 239000011777 magnesium Substances 0.000 description 6
• 229940091250 magnesium supplement Drugs 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 6
• 239000002207 metabolite Substances 0.000 description 6
• 229940102396 methyl bromide Drugs 0.000 description 6
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
• 229940016286 microcrystalline cellulose Drugs 0.000 description 6
• 239000008108 microcrystalline cellulose Substances 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 235000019198 oils Nutrition 0.000 description 6
• 229960002296 paroxetine Drugs 0.000 description 6
• 229940068196 placebo Drugs 0.000 description 6
• 239000000902 placebo Substances 0.000 description 6
• 239000000377 silicon dioxide Substances 0.000 description 6
• 210000000813 small intestine Anatomy 0.000 description 6
• 235000010413 sodium alginate Nutrition 0.000 description 6
• 239000000661 sodium alginate Substances 0.000 description 6
• 235000011121 sodium hydroxide Nutrition 0.000 description 6
• 238000003756 stirring Methods 0.000 description 6
• 239000003765 sweetening agent Substances 0.000 description 6
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
• 229960000575 trastuzumab Drugs 0.000 description 6
• PLIYGCKUMSKVCU-UHFFFAOYSA-N (4-hydroxyphenyl)-[4-[2-(methylamino)ethoxy]phenyl]methanone Chemical compound C1=CC(OCCNC)=CC=C1C(=O)C1=CC=C(O)C=C1 PLIYGCKUMSKVCU-UHFFFAOYSA-N 0.000 description 5
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 5
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
• AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 5
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 5
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 5
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 5
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 5
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 5
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
• 229910003074 TiCl4 Inorganic materials 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 229940081735 acetylcellulose Drugs 0.000 description 5
• 239000008186 active pharmaceutical agent Substances 0.000 description 5
• 150000001298 alcohols Chemical class 0.000 description 5
• 229910052782 aluminium Inorganic materials 0.000 description 5
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
• 229960000997 bicalutamide Drugs 0.000 description 5
• 239000001768 carboxy methyl cellulose Substances 0.000 description 5
• 229920002301 cellulose acetate Polymers 0.000 description 5
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 5
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 238000009093 first-line therapy Methods 0.000 description 5
• 235000003599 food sweetener Nutrition 0.000 description 5
• 235000011187 glycerol Nutrition 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229910052744 lithium Inorganic materials 0.000 description 5
• 229920003145 methacrylic acid copolymer Polymers 0.000 description 5
• 230000000683 nonmetastatic effect Effects 0.000 description 5
• 229910052700 potassium Inorganic materials 0.000 description 5
• 239000011591 potassium Substances 0.000 description 5
• 229960003975 potassium Drugs 0.000 description 5
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 210000004994 reproductive system Anatomy 0.000 description 5
• 229940005550 sodium alginate Drugs 0.000 description 5
• 239000000176 sodium gluconate Substances 0.000 description 5
• 235000012207 sodium gluconate Nutrition 0.000 description 5
• 229940005574 sodium gluconate Drugs 0.000 description 5
• 235000010356 sorbitol Nutrition 0.000 description 5
• 239000000600 sorbitol Substances 0.000 description 5
• MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 4
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 4
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 4
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
• 108010036949 Cyclosporine Proteins 0.000 description 4
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
• 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 4
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
• 229910002651 NO3 Inorganic materials 0.000 description 4
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
• AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
• 235000019270 ammonium chloride Nutrition 0.000 description 4
• 229910052788 barium Inorganic materials 0.000 description 4
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 4
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 4
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
• 229910052797 bismuth Inorganic materials 0.000 description 4
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 4
• 230000005907 cancer growth Effects 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 4
• 229960002023 chloroprocaine Drugs 0.000 description 4
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
• 229960001231 choline Drugs 0.000 description 4
• CJXAEXPPLWQRFR-UHFFFAOYSA-N clemizole Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1CN1CCCC1 CJXAEXPPLWQRFR-UHFFFAOYSA-N 0.000 description 4
• 229950002020 clemizole Drugs 0.000 description 4
• DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
• 239000001177 diphosphate Substances 0.000 description 4
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
• 235000011180 diphosphates Nutrition 0.000 description 4
• 229960004671 enzalutamide Drugs 0.000 description 4
• WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 4
• 229940011871 estrogen Drugs 0.000 description 4
• 239000000262 estrogen Substances 0.000 description 4
• 235000019253 formic acid Nutrition 0.000 description 4
• 229950006191 gluconic acid Drugs 0.000 description 4
• 229930195712 glutamate Natural products 0.000 description 4
• 229940074045 glyceryl distearate Drugs 0.000 description 4
• 229940075507 glyceryl monostearate Drugs 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 4
• 238000009169 immunotherapy Methods 0.000 description 4
• 208000030776 invasive breast carcinoma Diseases 0.000 description 4
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
• 229960001078 lithium Drugs 0.000 description 4
• IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 4
• 229940049920 malate Drugs 0.000 description 4
• BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 4
• 238000009607 mammography Methods 0.000 description 4
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 229960003194 meglumine Drugs 0.000 description 4
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 4
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
• 235000019161 pantothenic acid Nutrition 0.000 description 4
• 235000019371 penicillin G benzathine Nutrition 0.000 description 4
• 235000021317 phosphate Nutrition 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 4
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 4
• 229960004919 procaine Drugs 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 4
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
• 239000010936 titanium Substances 0.000 description 4
• 229910052719 titanium Inorganic materials 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 3
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
• LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 3
• LNGQDBJPFPIRBF-UHFFFAOYSA-N 2,2-dichloroethyl carbonochloridate Chemical compound ClC(Cl)COC(Cl)=O LNGQDBJPFPIRBF-UHFFFAOYSA-N 0.000 description 3
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
• 101150029707 ERBB2 gene Proteins 0.000 description 3
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
• 229920003134 Eudragit® polymer Polymers 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 206010020850 Hyperthyroidism Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 208000007054 Medullary Carcinoma Diseases 0.000 description 3
• 229920000881 Modified starch Polymers 0.000 description 3
• NYDCDZSEEAUOHN-IZHYLOQSSA-N N-Desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=CC=C1 NYDCDZSEEAUOHN-IZHYLOQSSA-N 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 229920001800 Shellac Polymers 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
• 229920002253 Tannate Polymers 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
• VBBSPGVSLKBZRW-UHFFFAOYSA-N [4-[2-(dimethylamino)ethoxy]phenyl]-(4-hydroxyphenyl)methanone Chemical compound C1=CC(OCCN(C)C)=CC=C1C(=O)C1=CC=C(O)C=C1 VBBSPGVSLKBZRW-UHFFFAOYSA-N 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 229940028652 abraxane Drugs 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 208000009956 adenocarcinoma Diseases 0.000 description 3
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 3
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 3
• 239000000783 alginic acid Substances 0.000 description 3
• 229960001126 alginic acid Drugs 0.000 description 3
• 150000004781 alginic acids Chemical class 0.000 description 3
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
• 125000000129 anionic group Chemical group 0.000 description 3
• 229910000019 calcium carbonate Inorganic materials 0.000 description 3
• 235000010216 calcium carbonate Nutrition 0.000 description 3
• 229960004562 carboplatin Drugs 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 3
• 229960001653 citalopram Drugs 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 229960004397 cyclophosphamide Drugs 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 230000017858 demethylation Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 229940043237 diethanolamine Drugs 0.000 description 3
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 229940065910 docefrez Drugs 0.000 description 3
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
• 229940115080 doxil Drugs 0.000 description 3
• 229940087477 ellence Drugs 0.000 description 3
• 229950005627 embonate Drugs 0.000 description 3
• 229960001904 epirubicin Drugs 0.000 description 3
• 229960003649 eribulin Drugs 0.000 description 3
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
• 229960004341 escitalopram Drugs 0.000 description 3
• 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 3
• RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
• 229940012017 ethylenediamine Drugs 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 229960002464 fluoxetine Drugs 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 238000010575 fractional recrystallization Methods 0.000 description 3
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
• 235000012208 gluconic acid Nutrition 0.000 description 3
• 229940118951 halaven Drugs 0.000 description 3
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
• 229960003943 hypromellose Drugs 0.000 description 3
• 208000024312 invasive carcinoma Diseases 0.000 description 3
• 229960002014 ixabepilone Drugs 0.000 description 3
• 229940111707 ixempra Drugs 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 208000019423 liver disease Diseases 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 230000000813 microbial effect Effects 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• OSFCMRGOZNQUSW-UHFFFAOYSA-N n-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10h-acridine-4-carboxamide Chemical compound N1C2=C(OC)C=CC=C2C(=O)C2=C1C(C(=O)NC1=CC=C(C=C1)CCN1CCC=3C=C(C(=CC=3C1)OC)OC)=CC=C2 OSFCMRGOZNQUSW-UHFFFAOYSA-N 0.000 description 3
• 229940086322 navelbine Drugs 0.000 description 3
• 238000009099 neoadjuvant therapy Methods 0.000 description 3
• 239000012044 organic layer Substances 0.000 description 3
• 229940014662 pantothenate Drugs 0.000 description 3
• 239000011713 pantothenic acid Substances 0.000 description 3
• 201000010198 papillary carcinoma Diseases 0.000 description 3
• 239000012188 paraffin wax Substances 0.000 description 3
• 235000019809 paraffin wax Nutrition 0.000 description 3
• 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 229960005141 piperazine Drugs 0.000 description 3
• 229940063179 platinol Drugs 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 3
• 229960001860 salicylate Drugs 0.000 description 3
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 3
• 229960002073 sertraline Drugs 0.000 description 3
• 235000013874 shellac Nutrition 0.000 description 3
• 239000004208 shellac Substances 0.000 description 3
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
• 229940113147 shellac Drugs 0.000 description 3
• 235000012239 silicon dioxide Nutrition 0.000 description 3
• CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 229940114926 stearate Drugs 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 229940063683 taxotere Drugs 0.000 description 3
• 208000022679 triple-negative breast carcinoma Diseases 0.000 description 3
• 201000007423 tubular adenocarcinoma Diseases 0.000 description 3
• 229960003740 vilazodone Drugs 0.000 description 3
• UXDQRXUZPXSLJK-UHFFFAOYSA-N vilazodone Chemical compound C1=CC(C#N)=C[C]2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CN=C21 UXDQRXUZPXSLJK-UHFFFAOYSA-N 0.000 description 3
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 3
• 229960002066 vinorelbine Drugs 0.000 description 3
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• 229950005752 zosuquidar Drugs 0.000 description 3
• MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 2
• ZGMJYTYLTJFNCS-VQYXCCSOSA-N (e)-but-2-enedioic acid;1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC2=NC=CC=C2C=1OCC(O)CN(CC1)CCN1C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 ZGMJYTYLTJFNCS-VQYXCCSOSA-N 0.000 description 2
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 2
• DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 2
• WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 2
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
• 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 2
• 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 2
• DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 2
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
• 208000006402 Ductal Carcinoma Diseases 0.000 description 2
• 229920003143 Eudragit® FS 30 D Polymers 0.000 description 2
• 229920003139 Eudragit® L 100 Polymers 0.000 description 2
• 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
• 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 208000000265 Lobular Carcinoma Diseases 0.000 description 2
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
• 244000246386 Mentha pulegium Species 0.000 description 2
• 235000016257 Mentha pulegium Nutrition 0.000 description 2
• 235000004357 Mentha x piperita Nutrition 0.000 description 2
• RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 239000004372 Polyvinyl alcohol Substances 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 229920002494 Zein Polymers 0.000 description 2
• 230000035508 accumulation Effects 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 229940064305 adrucil Drugs 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 229940023476 agar Drugs 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 2
• 239000000908 ammonium hydroxide Substances 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 235000013871 bee wax Nutrition 0.000 description 2
• 239000012166 beeswax Substances 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 201000003714 breast lobular carcinoma Diseases 0.000 description 2
• 229960003563 calcium carbonate Drugs 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 239000004203 carnauba wax Substances 0.000 description 2
• 235000013869 carnauba wax Nutrition 0.000 description 2
• 125000002091 cationic group Chemical group 0.000 description 2
• 229960000541 cetyl alcohol Drugs 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• IHOVFYSQUDPMCN-DBEBIPAYSA-N chembl444172 Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1[C@@H]1C2=CC=CC=C2[C@H]2C(F)(F)[C@H]2C2=CC=CC=C12 IHOVFYSQUDPMCN-DBEBIPAYSA-N 0.000 description 2
• 229940112822 chewing gum Drugs 0.000 description 2
• 235000015218 chewing gum Nutrition 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000019425 cirrhosis of liver Diseases 0.000 description 2
• 150000001860 citric acid derivatives Chemical class 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 239000000084 colloidal system Substances 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000002425 crystallisation Methods 0.000 description 2
• 230000008025 crystallization Effects 0.000 description 2
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
• XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
• SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000002124 endocrine Effects 0.000 description 2
• PQLFROTZSIMBKR-UHFFFAOYSA-N ethenyl carbonochloridate Chemical compound ClC(=O)OC=C PQLFROTZSIMBKR-UHFFFAOYSA-N 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 201000003585 eunuchism Diseases 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
• 238000001631 haemodialysis Methods 0.000 description 2
• 230000000322 hemodialysis Effects 0.000 description 2
• 229960003258 hexylresorcinol Drugs 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 235000001050 hortel pimenta Nutrition 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000011221 initial treatment Methods 0.000 description 2
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 208000037106 male hypogonadism Diseases 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229940117841 methacrylic acid copolymer Drugs 0.000 description 2
• IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 2
• 229960001047 methyl salicylate Drugs 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 2
• 239000004200 microcrystalline wax Substances 0.000 description 2
• 235000019808 microcrystalline wax Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• KADXVMRYQRCLAH-UHFFFAOYSA-N n'-iodobutanediamide Chemical compound NC(=O)CCC(=O)NI KADXVMRYQRCLAH-UHFFFAOYSA-N 0.000 description 2
• GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
• LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
• ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 2
• BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
• 229940078552 o-xylene Drugs 0.000 description 2
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 229940023488 pill Drugs 0.000 description 2
• 239000008389 polyethoxylated castor oil Substances 0.000 description 2
• 238000003752 polymerase chain reaction Methods 0.000 description 2
• 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 2
• 229920002451 polyvinyl alcohol Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 235000015497 potassium bicarbonate Nutrition 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 235000011181 potassium carbonates Nutrition 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 229940035613 prozac Drugs 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
• 238000003753 real-time PCR Methods 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 239000002002 slurry Substances 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 229960002920 sorbitol Drugs 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
• YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
• URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 125000005591 trimellitate group Chemical group 0.000 description 2
• 238000005292 vacuum distillation Methods 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 235000012431 wafers Nutrition 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• 229940093612 zein Drugs 0.000 description 2
• 239000005019 zein Substances 0.000 description 2
• KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
• SVJMLYUFVDMUHP-MGBGTMOVSA-N (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-MGBGTMOVSA-N 0.000 description 1
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
• CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
• MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
• RSJCLODJSVZNQA-BQYQJAHWSA-N 4-[2-[4-[(e)-3-ethoxyprop-1-enyl]phenyl]-4-[4-(propan-2-ylamino)phenyl]-1h-imidazol-5-yl]-n-propan-2-ylaniline Chemical compound C1=CC(/C=C/COCC)=CC=C1C1=NC(C=2C=CC(NC(C)C)=CC=2)=C(C=2C=CC(NC(C)C)=CC=2)N1 RSJCLODJSVZNQA-BQYQJAHWSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
• NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
• 241000321096 Adenoides Species 0.000 description 1
• 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 244000099147 Ananas comosus Species 0.000 description 1
• 235000007119 Ananas comosus Nutrition 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 244000075850 Avena orientalis Species 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 235000007558 Avena sp Nutrition 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 239000004135 Bone phosphate Substances 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000167854 Bourreria succulenta Species 0.000 description 1
• 206010006298 Breast pain Diseases 0.000 description 1
• 101150051438 CYP gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 102100033620 Calponin-1 Human genes 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
• 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 description 1
• PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 229920003149 Eudragit® E 100 Polymers 0.000 description 1
• 229920003150 Eudragit® E 12,5 Polymers 0.000 description 1
• 229920003136 Eudragit® L polymer Polymers 0.000 description 1
• 229920003141 Eudragit® S 100 Polymers 0.000 description 1
• 229920003142 Eudragit® S 12,5 Polymers 0.000 description 1
• 229920003137 Eudragit® S polymer Polymers 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 235000016623 Fragaria vesca Nutrition 0.000 description 1
• 240000009088 Fragaria x ananassa Species 0.000 description 1
• 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 101150050733 Gnas gene Proteins 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
• 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
• 208000033830 Hot Flashes Diseases 0.000 description 1
• 206010060800 Hot flush Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• DSLZVSRJTYRBFB-AJSXGEPRSA-N L-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-AJSXGEPRSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 208000006662 Mastodynia Diseases 0.000 description 1
• 229920003091 Methocel™ Polymers 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 239000008118 PEG 6000 Substances 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001602688 Pama Species 0.000 description 1
• IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
• 208000004605 Persistent Truncus Arteriosus Diseases 0.000 description 1
• 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
• 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
• HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
• 102100025803 Progesterone receptor Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 229920000297 Rayon Polymers 0.000 description 1
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
• 235000011552 Rhamnus crocea Nutrition 0.000 description 1
• 240000007651 Rubus glaucus Species 0.000 description 1
• 235000011034 Rubus glaucus Nutrition 0.000 description 1
• 235000009122 Rubus idaeus Nutrition 0.000 description 1
• YJDYDFNKCBANTM-QCWCSKBGSA-N SDZ PSC 833 Chemical compound C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O YJDYDFNKCBANTM-QCWCSKBGSA-N 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 239000004376 Sucralose Substances 0.000 description 1
• 235000019486 Sunflower oil Nutrition 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• LGGHDPFKSSRQNS-UHFFFAOYSA-N Tariquidar Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC(OC)=C(OC)C=C3C(=O)NC3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CN=C21 LGGHDPFKSSRQNS-UHFFFAOYSA-N 0.000 description 1
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000037258 Truncus arteriosus Diseases 0.000 description 1
• 206010046798 Uterine leiomyoma Diseases 0.000 description 1
• 241000759263 Ventia crocea Species 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
• QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000000619 acesulfame-K Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 210000002534 adenoid Anatomy 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 241001148470 aerobic bacillus Species 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000010775 animal oil Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000010692 aromatic oil Substances 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 238000003339 best practice Methods 0.000 description 1
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• MPCVYAVDVXEPTK-UHFFFAOYSA-N butane Chemical compound CCC[CH2+] MPCVYAVDVXEPTK-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229960005069 calcium Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000004227 calcium gluconate Substances 0.000 description 1
• 235000013927 calcium gluconate Nutrition 0.000 description 1
• 229960004494 calcium gluconate Drugs 0.000 description 1
• 229960001714 calcium phosphate Drugs 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
• 239000010495 camellia oil Substances 0.000 description 1
• 239000012830 cancer therapeutic Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 229940047493 celexa Drugs 0.000 description 1
• 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 239000012829 chemotherapy agent Substances 0.000 description 1
• 235000019693 cherries Nutrition 0.000 description 1
• FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical group ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
• 229960003338 crotamiton Drugs 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 229940109275 cyclamate Drugs 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 229960000935 dehydrated alcohol Drugs 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 229950002422 dexniguldipine Drugs 0.000 description 1
• 229940096516 dextrates Drugs 0.000 description 1
• SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
• 229950005878 dexverapamil Drugs 0.000 description 1
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
• 229940031569 diisopropyl sebacate Drugs 0.000 description 1
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Substances CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 108010037444 diisopropylglutathione ester Proteins 0.000 description 1
• XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
• SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000009506 drug dissolution testing Methods 0.000 description 1
• 229950005476 elacridar Drugs 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 238000003821 enantio-separation Methods 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 229960004667 ethyl cellulose Drugs 0.000 description 1
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 201000010103 fibrous dysplasia Diseases 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 229940013317 fish oils Drugs 0.000 description 1
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 229960003681 gluconolactone Drugs 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 239000001087 glyceryl triacetate Substances 0.000 description 1
• 235000013773 glyceryl triacetate Nutrition 0.000 description 1
• 229960002389 glycol salicylate Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 230000010224 hepatic metabolism Effects 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229910001867 inorganic solvent Inorganic materials 0.000 description 1
• 239000003049 inorganic solvent Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 229920003049 isoprene rubber Polymers 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 229940054157 lexapro Drugs 0.000 description 1
• 229940059904 light mineral oil Drugs 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 229940071260 lithium gluconate Drugs 0.000 description 1
• ZOTSUVWAEYHZRI-JJKGCWMISA-M lithium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Li+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O ZOTSUVWAEYHZRI-JJKGCWMISA-M 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000001365 lymphatic vessel Anatomy 0.000 description 1
• 239000001755 magnesium gluconate Substances 0.000 description 1
• 235000015778 magnesium gluconate Nutrition 0.000 description 1
• 229960003035 magnesium gluconate Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 201000003175 male breast cancer Diseases 0.000 description 1
• 208000010907 male breast carcinoma Diseases 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 235000010449 maltitol Nutrition 0.000 description 1
• 239000000845 maltitol Substances 0.000 description 1
• VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
• 229940035436 maltitol Drugs 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 230000037353 metabolic pathway Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 229910052750 molybdenum Inorganic materials 0.000 description 1
• 239000011733 molybdenum Substances 0.000 description 1
• JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229910052758 niobium Inorganic materials 0.000 description 1
• 239000010955 niobium Substances 0.000 description 1
• GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
• 229960000381 omeprazole Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 229960005019 pantoprazole Drugs 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 229960000292 pectin Drugs 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 229940028296 pexeva Drugs 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 229960000540 polacrilin potassium Drugs 0.000 description 1
• 229920001083 polybutene Polymers 0.000 description 1
• 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 235000010408 potassium alginate Nutrition 0.000 description 1
• 239000000737 potassium alginate Substances 0.000 description 1
• MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 239000004224 potassium gluconate Substances 0.000 description 1
• 235000013926 potassium gluconate Nutrition 0.000 description 1
• 229960003189 potassium gluconate Drugs 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229940114930 potassium stearate Drugs 0.000 description 1
• WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
• ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 235000019814 powdered cellulose Nutrition 0.000 description 1
• 229920003124 powdered cellulose Polymers 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000004886 process control Methods 0.000 description 1
• 108090000468 progesterone receptors Proteins 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• FLALGSYYVIWTFQ-UHFFFAOYSA-K propan-2-olate;titanium(4+);trichloride Chemical compound [Cl-].[Cl-].[Cl-].CC(C)O[Ti+3] FLALGSYYVIWTFQ-UHFFFAOYSA-K 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
• 230000001698 pyrogenic effect Effects 0.000 description 1
• 150000004040 pyrrolidinones Chemical class 0.000 description 1
• 229960001404 quinidine Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 208000015608 reproductive system cancer Diseases 0.000 description 1
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
• 229960003147 reserpine Drugs 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
• 239000005060 rubber Substances 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 239000011833 salt mixture Substances 0.000 description 1
• QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
• 229960001852 saquinavir Drugs 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 229920002545 silicone oil Polymers 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 229940001593 sodium carbonate Drugs 0.000 description 1
• 235000017550 sodium carbonate Nutrition 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 229960003339 sodium phosphate Drugs 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 229940032094 squalane Drugs 0.000 description 1
• 229940031439 squalene Drugs 0.000 description 1
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
• 235000019408 sucralose Nutrition 0.000 description 1
• BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 235000021092 sugar substitutes Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000002600 sunflower oil Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000009121 systemic therapy Methods 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000003784 tall oil Substances 0.000 description 1
• 229950002757 teoclate Drugs 0.000 description 1
• UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
• UBZYKBZMAMTNKW-UHFFFAOYSA-J titanium tetrabromide Chemical compound Br[Ti](Br)(Br)Br UBZYKBZMAMTNKW-UHFFFAOYSA-J 0.000 description 1
• XROWMBWRMNHXMF-UHFFFAOYSA-J titanium tetrafluoride Chemical compound [F-].[F-].[F-].[F-].[Ti+4] XROWMBWRMNHXMF-UHFFFAOYSA-J 0.000 description 1
• NLLZTRMHNHVXJJ-UHFFFAOYSA-J titanium tetraiodide Chemical compound I[Ti](I)(I)I NLLZTRMHNHVXJJ-UHFFFAOYSA-J 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 229960002622 triacetin Drugs 0.000 description 1
• 239000001069 triethyl citrate Substances 0.000 description 1
• 235000013769 triethyl citrate Nutrition 0.000 description 1
• VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 229960001722 verapamil Drugs 0.000 description 1
• 229940001789 viibryd Drugs 0.000 description 1
• RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000005945 von Braun degradation reaction Methods 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
• 229960000317 yohimbine Drugs 0.000 description 1
• AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
• 229940057977 zinc stearate Drugs 0.000 description 1
• 229910052726 zirconium Inorganic materials 0.000 description 1
• 229940020965 zoloft Drugs 0.000 description 1
• IHOVFYSQUDPMCN-QKUIIBHLSA-N zosuquidar Chemical compound C([C@H](COC=1C2=CC=CN=C2C=CC=1)O)N(CC1)CCN1C1C2=CC=CC=C2C2C(F)(F)C2C2=CC=CC=C12 IHOVFYSQUDPMCN-QKUIIBHLSA-N 0.000 description 1